Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by $0.12, Briefing.com reports. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million. Adamas Pharmaceuticals had a negative return on equity of 45.19% and a negative net margin of 10,499.65%. Adamas Pharmaceuticals’s quarterly revenue was down 90.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.78) EPS.

Adamas Pharmaceuticals (ADMS) traded down 2.545% during trading on Wednesday, hitting $16.392. The stock had a trading volume of 406,314 shares. The firm has a 50 day moving average price of $17.38 and a 200-day moving average price of $16.85. Adamas Pharmaceuticals has a 1-year low of $12.10 and a 1-year high of $19.50. The firm’s market capitalization is $366.51 million.

TRADEMARK VIOLATION NOTICE: “Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Announces Earnings Results” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/adamas-pharmaceuticals-inc-nasdaqadms-announces-earnings-results/1466075.html.

In other news, major shareholder Great Point Partners Llc sold 350,000 shares of the stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $17.05, for a total transaction of $5,967,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 731,041 shares of company stock worth $12,476,149. Corporate insiders own 29.00% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Emerald Advisers Inc. PA increased its position in shares of Adamas Pharmaceuticals by 2.7% in the second quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock worth $9,317,000 after buying an additional 14,042 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Adamas Pharmaceuticals by 212.9% in the first quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock worth $1,066,000 after buying an additional 41,436 shares during the period. Geode Capital Management LLC increased its position in shares of Adamas Pharmaceuticals by 4.9% in the first quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock worth $2,201,000 after buying an additional 5,920 shares during the period. Vanguard Group Inc. increased its position in shares of Adamas Pharmaceuticals by 10.3% in the first quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock worth $12,537,000 after buying an additional 66,825 shares during the period. Finally, American International Group Inc. increased its position in shares of Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 682 shares during the period. Institutional investors own 71.33% of the company’s stock.

A number of brokerages have weighed in on ADMS. Cowen and Company set a $45.00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday. BidaskClub downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Mizuho reissued a “buy” rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 6th. Finally, Noble Financial reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Friday, May 12th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $29.00.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.